Clearbridge Investments LLC Grows Stock Holdings in Roivant Sciences Ltd. $ROIV

Clearbridge Investments LLC lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 7.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,972,921 shares of the company’s stock after buying an additional 141,549 shares during the quarter. Clearbridge Investments LLC’s holdings in Roivant Sciences were worth $42,812,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its stake in shares of Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Allworth Financial LP lifted its stake in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Fifth Third Bancorp lifted its stake in shares of Roivant Sciences by 15.8% during the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after buying an additional 588 shares in the last quarter. Finally, Utah Retirement Systems lifted its stake in shares of Roivant Sciences by 3.0% during the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after buying an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction on Monday, March 16th. The shares were sold at an average price of $28.68, for a total value of $1,200,573.48. Following the sale, the director directly owned 15,804 shares in the company, valued at approximately $453,258.72. The trade was a 72.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the sale, the chief executive officer owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 945,173 shares of company stock valued at $27,654,456. 10.80% of the stock is currently owned by insiders.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $29.05 on Wednesday. The company has a market cap of $20.89 billion, a P/E ratio of -48.42 and a beta of 1.13. The firm’s fifty day moving average is $28.83 and its two-hundred day moving average is $25.83. Roivant Sciences Ltd. has a 52-week low of $10.70 and a 52-week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period in the previous year, the firm posted ($0.29) EPS. As a group, analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ROIV. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Citigroup lifted their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, TD Cowen lifted their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.